Genzyme's Renvela approved in EU for chronic kidney disease
This article was originally published in Scrip
Executive Summary
Genzyme has received an EU approval for Renvela (sevelamer carbonate) in both tablet and powder formulations, for the control of hyperphosphataemia in patients with chronic kidney disease with serum phosphorous levels above 1.78mmol/l, regardless of whether they are receiving dialysis.